Yabao Pharmaceutical: Obtained the registration certificate for the compound polyethylene glycol electrolyte soluble medication.

Yabao Pharmaceuticals announced that it has recently received the drug registration certificate for compound polyethylene glycol electrolyte powder approved and issued by the National Medical Products Administration. This drug is mainly used to treat chronic constipation and fecal impaction in children. It was approved for sale in Japan in November 2018, but is not yet on the market domestically in China. Sales data for this drug in domestic public hospitals and retail pharmacies is projected to be 2.86 million yuan in 2024. As of the date of the announcement, a total of 18 companies in China have received approval to register this drug, with the company having invested 2.12 million yuan in research and development costs. The company plans to move forward with production and sales of this product, but there are uncertainties in the process.